Tiotropium 5 Microgram (μg) vs Tiotropium (5 μg) + Olodaterol (5 μg): deaths from any cause
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
Measures 6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note | Source |
|---|---|---|---|---|---|---|
| Risk in group 1 | 0.0249 | 0.0204 | 0.0302 | wilson | ClinicalTrials.gov | |
| Risk in group 2 | 0.0234 | 0.0191 | 0.0286 | wilson | ClinicalTrials.gov | |
| Risk difference, group 1 minus group 2 | 0.00151 | -0.00531 | 0.00835 | newcombe hybrid score | ClinicalTrials.gov | |
| Risk ratio, group 1 over group 2 | 1.06 | 0.804 | 1.41 | log | ClinicalTrials.gov | |
| Odds ratio, group 1 over group 2 | 1.07 | 0.799 | 1.42 | log | ClinicalTrials.gov | |
| Number needed to harm, for one more death from any cause on Tiotropium 5 Microgram (μg) than on Tiotropium (5 μg) + Olodaterol (5 μg) | 662 | from the risk difference interval | the interval includes no difference | ClinicalTrials.gov |
Groups 2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code | Source |
|---|---|---|---|---|---|---|
| Group 1 | Tiotropium 5 Microgram (μg) | Patient received 5 μg Tiotropium inhalation solution - RESPIMAT inhaler once daily orally for 360 days | 98 | 3,941 | EG000 | ClinicalTrials.gov |
| Group 2 | Tiotropium (5 μg) + Olodaterol (5 μg) | Patient received 5 μg Tiotropium + 5 μg Olodaterol fixed-dose combination (FDC) inhalation solution - RESPIMAT inhaler once daily orally for 360 days | 92 | 3,939 | EG001 | ClinicalTrials.gov |
Harm 2
| Field | Value | Source |
|---|---|---|
| What it counts | Total, all-cause mortality | ClinicalTrials.gov |
| Time frame | From the first dose of trial medication until 21 days after last in-take of trial medication, up to 381 days | ClinicalTrials.gov |
Trial 8
| Field | Value | Source |
|---|---|---|
| Title | Comparing the Efficacy of Tiotropium + Olodaterol (5/5 µg) Fixed Dose Combination (FDC) Over Tiotropium 5µg in Reducing Moderate to Severe Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease. | ClinicalTrials.gov |
| NCT number | NCT02296138 | ClinicalTrials.gov |
| Phases | PHASE3 | ClinicalTrials.gov |
| Conditions | Pulmonary Disease, Chronic Obstructive | ClinicalTrials.gov |
| Interventions | olodaterol, tiotropium, tiotropium | ClinicalTrials.gov |
| Lead sponsor | Boehringer Ingelheim | ClinicalTrials.gov |
| Results first posted | 2018-06-04 | ClinicalTrials.gov |
| Results on ClinicalTrials.gov | https://clinicaltrials.gov/study/NCT02296138?tab=results | ClinicalTrials.gov |
Source 4
| Field | Value | Source |
|---|---|---|
| Release | trial-comparisons-2026-03-23-0.1.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57 | ClinicalTrials.gov |
| AACT copy | 2026-03-23 | ClinicalTrials.gov |
| Tables read | outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet | ClinicalTrials.gov |
Release trial-comparisons-2026-03-23-0.1.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.